[ad_1] Carl Icahn speaking at Delivering Alpha in New York on Sept. 13, 2016. David A. Grogan | CNBC Carl Icahn on Thursday expressed his support for Illumina‘s new CEO Jacob Thaysen – a relief for the company as it tries to rebound from a bitter proxy fight with the billionaire activist investor. “I think…
[ad_1] A building on the campus at the world headquarters of Illumina is shown in San Diego, California, Sept. 1, 2021. Mike Blake | Reuters Illumina‘s board on Tuesday named Jacob Thaysen as the DNA sequencing company’s new CEO as it tries to rebound from a grinding dispute over its acquisition of cancer test developer…
[ad_1] A building on the campus at the world headquarters of Illumina is shown in San Diego, California, September 1, 2021. Mike Blake | Reuters The Securities and Exchange Commission is investigating Illumina over its controversial $7.1 billion acquisition of cancer test developer Grail, the DNA sequencing company said in a securities filing late Thursday. …
[ad_1] Rafael Henrique | Lightrocket | Getty Images European Union regulators on Wednesday fined Illumina a record 432 million euros ($476 million) for closing its acquisition of cancer test developer Grail without first securing regulatory approval. The fine from the European Commission, the EU’s executive body, amounts to 10% of San Diego-based Illumina‘s turnover. That…
[ad_1] Rafael Henrique | Lightrocket | Getty Images Republican lawmakers, state attorneys general and several advocacy groups have voiced their support for Illumina’s acquisition of cancer-test developer Grail while the Federal Trade Commission fights to unwind the deal. The groups filed 14 amicus briefs Monday urging the U.S. 5th Circuit Court of Appeals to reverse…
[ad_1] Francis deSouza, chief executive officer of Illumina Inc., during a panel session on day three of the World Economic Forum (WEF) in Davos, Switzerland, on Thursday, Jan. 19, 2023. Stefan Wermuth | Bloomberg | Getty Images Illumina on Sunday announced its board of directors has accepted the resignation of CEO Francis deSouza, just weeks…
[ad_1] Rafael Henrique | Lightrocket | Getty Images Activist investor Carl Icahn on Thursday won enough support from Illumina shareholders to oust the biotech company’s board chair. Shareholders booted Chairman John Thompson. An Illumina spokesperson said a new chair will be chosen in the next few weeks. Icahn had urged shareholders to vote off the…
[ad_1] The Federal Trade Commission on Tuesday filed a lawsuit seeking to block drug giant Amgen‘s $27.8 billion acquisition of Horizon Therapeutics, arguing that the deal would “stifle competition” in the pharmaceutical industry. The FTC said that the deal would allow Amgen to “entrench the monopoly positions” of two of Horizon’s fast-growing medications: the thyroid…
[ad_1] Carl Icahn speaking at Delivering Alpha in New York on Sept. 13, 2016. David A. Grogan | CNBC Carl Icahn on Friday called Illumina’s first-quarter results “very disappointing” and slammed the DNA sequencing company’s new plans to cut costs. The activist investor, who owns a 1.4% stake in Illumina, is in a heated proxy…
[ad_1] A building on the campus at the world headquarters of Illumina is shown in San Diego, California, September 1, 2021. Mike Blake | Reuters Illumina on Tuesday unveiled plans to cut costs in a bid to improve the DNA sequencing company’s shrinking margins. The plans aim to reduce Illumina’s annualized run rate expenses by…
